Discover and read the best of Twitter Threads about #psilocybin

Most recents (24)

1/ The first study on the effects of 2C-B has just been published! 🍭

By comparing 2C-B to #psilocybin it was found that the two drugs induced similar subjective alterations, with 2C-B possessing less experiential depth than psilocybin but greater euphoric and bodily qualities. Image
2/ 2C-B was found to elicit significant elevations across most scales outside of auditory alterations, disembodiment, and spiritual experience. However, the overall magnitude of alterations to waking consciousness (total 5D-ASC score) was markedly less than that of psilocybin.
3/ Participants under the influence of psilocybin also reported a greater propensity for affective qualities of altered self-experience (ego dissolution) as well as emotional lability. Image
Read 6 tweets
Today's Twitter threads (a Twitter thread).

Inside: Care Inflation; and more!

Archived at:…

#Pluralistic 1/ The old woman in the shoe. She stands before her shoe, weari
Tomorrow (1/19) at 1530hPT, I'm joining my co-author @rgibli and our host, @BradStone, for an @InternetArchive/@Coil livecast about our book #ChokepointCapitalism: 2/
Care Inflation: The inflation no one wants to talk about.

Read 22 tweets
Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial:…. The results of our #psilocybin-assisted therapy for #depression study are published.
If you don’t feel like reading the entire article during your winter break, here is a brief summary:
A single dose of psilocybin in combination with psychological support significantly decreased symptom severity in a group of MDD patients compared to patients who received psychological support and a placebo.
Read 9 tweets
In the @COMPASSPathway trial the 25mg vs 1mg (=placebo) #Psilocybin difference is not only significant statistically, but also clinically. On the MADRS the 'minimal important difference' is ~3-6 points (, the 25mg dose meets this criteria (more context 👇)
The 'minimal important difference' sounds like a low bar to cross, but actually most #antidepressants fail to do so relative to #placebo, - thank you @PloederlM for your work on this, would love to hear your take on this trial!
Lack of blinding remains an issue, but the dose-response relationship should alleviate this concern. As I argued before, #psychedelics macrodose trials most likely will always lack blinding due to obvious drug effects, it is the nature of the intervention.
Read 4 tweets
New article out now regarding the pharmacology of #psilocybin analogues including other compounds found in psilocybin-containing mushrooms, their active metabolites, and 4-acetoxy derivatives.…

#pharmacology #psychedelics #aeruginascin #baeocystin
This was truly an amazing team effort by many folks from @usonainstitute, @CaaMTechInc, @christophestove, Manke lab, Hulley lab, and NIDA IRP DDRU.

Keep an eye out for many more publications from us investigating the #pharmacology of #psychedelics !
Oh and I certainly can't forget to thank the NIMH PDSP for their role in these projects!
Read 3 tweets
A PQ from @OwenThompson MP, on the evidence for the classification of #psilocybin (the drug in magic mushrooms) in class A, has produced an interesting answer from new drugs mininster Jeremy Quin MP

IMHO it's quite a misleading answer, thats usefully unpicked....

@OwenThompson In response to the evidence request Quin states:

"Govt has not commissioned or published any recent analysis of the harms of psilocybin"

'Recent' suggests that their was evidence in the past

There wasnt

He should have said none has EVER been commissioned or published
@OwenThompson Psilocybin's anomalous classification came up in The Sci-Tech Select Committee 2006 inquiry, when ACMD chair Micheal Rawlins conceded:

“I've no idea what was going through the minds of the group who put it in ClassA...It is there because it is there”…
Read 12 tweets
My first 1st author paper is out in @TheBJPsych ! We found out that psilocybin is superior in reducing rumination and chronic suppression of negative emotions compared to escitalopram. Big thanks to @RCarhartHarris and @LeorRoseman for the guidance. #Psilocybin #psychiatry #LSD Image
Rumination and thought suppression are 2 maladaptive coping strategies and, despite appearing sort of opposite, they reinforce each others (suppressed thoughts usually come back stronger, fuelling rumination).
While psilocybin appeared superior to escitalopram in reducing both of those maladaptive strategies, we wanted to see if psilocybin was just superior of if the effect was specific.
Read 7 tweets
1/ #Oregon Health Authority publishes latest draft #psilocybin rules to implement Measure 109. Some early thoughts: First, the rules allow for a variation of #microdosing. Clients could consume up to 5mg and potentially leave a center after 1 hour.…
2/ Under the draft rules, the minimum length of administration sessions would vary based on the dose of #psilocybin received. Clients consuming 5 - 10mg could potentially leave after 2 hours, and 15 - 25mg would require a minimum stay of 4 hours.
3/ The facilitator to client ratios will also change depending on the doses of #psilocybin received, ranging from a potential 8 clients to each facilitator for doses of 5 - 10mg to no more than 1 client for every facilitator for doses between 40 - 50mg.
Read 16 tweets
The recent #psilocybin vs. alcoholism trial used an active placebo (diphenhydramine). Despite this ~94% correctly guessed their treatment, showing that blinding didn't work. IMO this shows that active placebos likely wont solve the blinding issue of #psychedelic trials, a 🧵
Active placebos may have perceivable effects, but these wont confuse most patients, because psychedelics have very specific subjective effects. When a patient experiences drug effects, in most cases its easy to decipher whether its due to a psychedelic or some other drug.
Even if someone is unfamiliar with psychedelic effects going into a trial, modern ethical research standards require doctors to discuss likely effects with patients, making blind breaking that much easier
Read 7 tweets
If you are thinking about taking #psilocybin for the first time. There are six aspects to maximize your potential for safety, growth, healing, and enjoyment.

here is a thread about them. 🧵

we also have a class, starting in Oct about this topic -
1) Set

Preparing your mindset with contemplation, self care, and support.

Practicing meditation, journaling, and introspection to determine your goals, and if this is really the right time for this journey...
2) Setting

Creating an environment & atmosphere conducive to the experience that you want

Make sure it's safe, clean, and pleasant!
Read 8 tweets
The 'default mode network' (#DMN) is the neurobiological poster child for #psychedelic #drugs (e.g., see #HowToChangeYourMind). A preliminary meta-analysis from the @PsychedelicUNIT suggests this might be overstated, w/ other regions being more impacted, like ye olde cerebellum. Image
These results are from 'classic' #psychedelics like #LSD and #psilocybin taken by healthy people during resting-state neuroimaging. We used dose as a covariate. A possible caveat is that we mixed blob and functional connectivity analyses which we will now try and model.
The details will soon be in a preprint and we will make the code and larger dataset publicly available. We hope this will help others to address their own questions with further meta-analyses. For example, we asked....
Read 8 tweets
Time for another #sciencetwitter journal club! Today's paper: #Microdosing with #psilocybin #mushrooms: a double-blind placebo-controlled study by Cavanna et al 2022! Hot off the presses!…
This study has:

34 participants, about half of which had previous experience with psychedelics

Randomized, double-blind placebo-controlled, within-subjects design

0.5. g psilocybin mushroom in capsule and edible, non-psychedelic mushroom as placebo
typical "microdose" is 0.1 - 0.5 g of dried mushrooms, which still can produce some type of altered consciousness, hallucination effect depending on the person.

most common regimen is 1 day on 2 days off, based on Fadiman's work.
Read 17 tweets
1/ @michaelpollan's highly-expected @netflix series #HowToChangeYourMind just premiered! 📺🍄 Despite near-universal praise, #HTCYM is rife with errors & borders on historical revisionism 🤥

A critique 🤔🧵 #LSD #MDMA #Peyote #Mescaline #Psilocybin #Mushrooms #Psychedelic @MAPS
2/ Before I get started, I'll give everyone a little bit of background information. @michaelpollan released a non-fiction work entitled "How to Change Your Mind" in May of 2018. Before the end of that year, his book about #psychedelic drugs became a @nytimes bestseller. Image
3/ @michaelpollan achieved massive coverage for this self-described "mental travelogue" of his #psychedelic experiences. Soon enough, Mr. Pollan became a prominent figure w/in the so-called "Psychedelic Renaissance". In the process, he gained a rather interesting reputation. Image
Read 104 tweets
Prof Jo Neill (@b_neuro) is about to give evidence to the @CommonsHomeAffs Select Committee, on the health, economic, and research cases for rescheduling #psilocybin for #mentalhealth treatment.

Watch the session here 👇…
@b_neuro @CommonsHomeAffs On whether the UK's current drug regulations are fit for purpose, Prof Neill says "clearly not", as they're not based on evidence, and inhibits research & innovation by throwing up barriers to research.
@b_neuro @CommonsHomeAffs Schedule 1 is reserved for drugs with "no medicinal value and causes a great deal of harm", but the evidence is clear psilocybin *has* medicinal value, and does not cause significant harm, especially when used in clinical settings.
Read 16 tweets
Thread 🧵

BREAKING: Health Canada has just notified TheraPsil and dozens of health care professionals seeking psilocybin access and training that their section 56 exemptions are to be denied. (1/ )
This will affect 1000+ health care professionals on our training waiting list and thousands of patients who are seeking help in applying for section 56 and SAP access to #psilocybin. (2/ )
This decision from @GovCanHealth lacks compassion and foresight. This is an issue of patient access and safety. By denying access, Health Canada is forcing patients and practitioners underground. (3/ )

CC: @jyduclos & @Carolyn_Bennett
Read 9 tweets
Minister @jyduclos,

Registered counsellors, like Carmen, are urgently asking you to approve their section 56 exemptions so they may finish training and be best prepared to facilitate safe and effective #psilocybintherapy for patients.

Please respond.

Minister @jyduclos - HCP's have now waited over 300 days for their exemptions. Why are these healthcare professionals not equal to their peers whose exemptions were approved back in December 2020? Why are you blocking access to the tools these HCPs need for training?
Minister @jyduclos - When you approve exemptions for HCP's you allow patients to access professionals fully trained in this unique modality. When you deny exemptions for training, patients are the one's who are impacted. Do the right thing. Grant HCP exemptions today.
Read 5 tweets
🧵"Psychoplastogens" = drugs that rapidly induce physical changes in the brain (neuroplasticity).

Examples: ketamine, psilocybin, LSD, DMT, MDMA.

Neuroscientists can literally watch new connections sprout overnight, as in the example below.


There are other plasticity-promoting psychoactive drugs, such as SSRIs, that are not psychoplastogens because they induce plasticity on a slower time scale (weeks).

Psychoplastogens can stimulate plasticity when exposed to neurons for <1 hour.…

I first learned about this term from the work of @DEOlsonLab.

I discussed his research with him in a recent podcast conversation, including his work on #psychedelics like ibogaine.

Listen here:

Read 6 tweets
Today is the second day of psychedelics @NIH 🇺🇲 with a critical issue to be tackled:

What is a #controlled study with psychedelics?

How to do it?

Why is it important?
Starting now with Michael Bogenschutz from @nyuniversity discussing what was left in the background yesterday: subjective effects
Mixed correlation results between MEQ subjective ratings and therapeutic outcomes for alcohol abuse 🤔
Read 36 tweets
For my first thread in 2022, I’m going to talk about another #psilocybin therapy company
Ticker: $PHRM
Price: ~C$0.37
Market cap: ~C$32 M
Investment style: Speculative
cc @psychstockwatch, @shroombom1000, @MicrodoseHQ
1/17 $PHRM is a clinical stage psychedelic company with focus on psychedelics use as prescription drugs.
2/17 @Pharmather_Inc is focusing on ketamine delivery via different formulations and a microneedle transdermal patch for intradermal delivery.
Read 18 tweets
From Psychiatry to Neurology: #Psychedelics as Prospective Therapeutics for Neurodegenerative Disorders 1/5…
The studies of #psychedelics, especially psychedelic tryptamines like #psilocybin, are rapidly gaining interest in neuroscience research. Much of this interest stems from recent clinical studies demonstrating that they have a unique ability t... 2/5
o improve the debilitating symptoms of major depressive disorder (MDD) long-term after only a single treatment. Indeed, the Food and Drug Administration (FDA) has recently designated two Phase III clinical trials studying the ability of psi... 3/5
Read 5 tweets
It’s official. I just receive a U01 grant from NIDA to study #psilocybin for tobacco addiction. To my knowledge it's the 1st grant from the US government in over a half century to directly study therapeutics of a classic #psychedelic. New era in legitimacy of psychedelic science.
This will be a multi-site trial with Hopkins as the lead site. The other sites will be NYU (site lead Michael Bogenschutz) and UAB (site lead Peter Hendricks).
I feel like a curse on this science is starting to lift. Best expressed as the musical movement that starts at 8:03 in this masterpiece
Read 3 tweets
We’ve got big news! Today we’re announcing 6 company acquisitions. Each of these companies has something unique to offer and we’re thrilled to help build their futures. $RNWF @alkabadshah
@alkabadshah We've acquired @SacredBioscienc, who is pioneering the future of psychedelic research, #psilocybin farming, and alternative therapeutics. Learn more about their mission below! $RNWF @alkabadshah Image
@alkabadshah @SacredBioscienc We acquired @sunshine_hemp. They are committed to helping Florida Farmers with the Best Hemp genetics for #CBD, #CBG, and other #hemp-derived products. $RNWF @alkabadshah Image
Read 7 tweets
A Yale study of 10 patients found 1 dose of #psilocybin can cut #migraine frequency in half for 2 weeks. Each patient did 1 session with placebo, 1 with the drug. People who felt most high got the least migraine relief. /thread…
The Yale researchers who conducted the small, but 1st of its kind study suggest #migraine patients might benefit from microdoses or sub-hallucinogenic doses of #psilocybin. Understanding how psilocybin prevents migraine might open new pathways for drug development, as well.
I did 2 #migraine clinical trials. I'm glad someone else took this one for the team. I hated Methysergide (Sansert), now discontinued, which was synthesized from lysergic #acid. A 1965 study said Sansert users experienced a "confused feeling of unreality." Tell me about it.
Read 7 tweets
Why we donated $150,000 to legalize & regulate #psilocybin (mushroom) therapy in Oregon.…
#Psychedelic medicines, when used responsibly in therapeutic settings, are effective tools for awakening compassion, healing trauma & catalyzing progressive social change.
Read 8 tweets

Related hashtags

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3.00/month or $30.00/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!